Xenetic Biosciences, Inc. — 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020; filed March 16, 2021. This is an annual report, not a standalone fourth-quarter filing, and the supplied text does not provide a clear Q4-only financial breakdown.
Business context and reporting period
Xenetic is a clinical-stage biopharmaceutical company prioritizing preclinical development of XCART, a personalized CAR T platform initially targeting B-cell lymphomas. The company also licenses its PolyXen drug-delivery technology and receives royalties. No company drug candidate had marketing approval. Development of XBIO-101 was suspended, with no current plan to resume it; future internal development is expected to focus primarily on XCART.
Key financial metrics
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue, entirely royalty revenue | $437,000 | $17,000 |
| Research and development expense | $1.73 million | $4.89 million |
| General and administrative expense | $3.40 million | $4.73 million |
| Asset impairment charges | $9.24 million | $3.28 million |
| Operating loss | $13.94 million | $12.89 million |
| Net loss | $10.89 million | $12.78 million |
| Net cash used in operating activities | $4.27 million | $6.40 million |
Royalty revenue increased largely because 2020 included a full year of Takeda-related royalties versus about three months in 2019. The company remained loss-making; conventional gross-margin measures are not meaningful for its royalty-led revenue and development-stage operations. The 2020 net loss included a $9.24 million non-cash impairment of the OncoHist in-process R&D asset, partly offset by a $2.92 million income tax benefit from reversal of the associated deferred tax liability. Basic and diluted loss per share was $1.70, compared with $6.33 in 2019; 2019 included a $5.28 million deemed dividend affecting loss applicable to common stockholders.
At year-end, cash was $11.53 million, working capital was approximately $11.4 million, total current assets were $12.37 million, current liabilities were $937,000, total liabilities were $964,000, and stockholders’ equity was $12.22 million. Total assets were $13.18 million. No material debt balance is shown in the balance sheet; reported long-term liabilities included lease liabilities. Financing cash flow was $5.43 million net proceeds from the December 2020 equity offering. The company reported no investing cash flow in 2020.
Material changes versus 2019
- Revenue rose by approximately $420,000, reflecting the full-year effect of Takeda sublicense royalties.
- R&D expense declined 64.6%, primarily because 2019 included $3.0 million of XCART acquisition-related IPR&D expense; excluding that item, R&D fell about 6.8%.
- G&A expense fell 28.1%, mainly because 2019 included about $1.1 million of XCART acquisition transaction costs.
- Impairment charges increased: 2020’s $9.24 million charge eliminated the remaining OncoHist IPR&D asset; 2019’s $3.28 million charge eliminated goodwill.
- Net loss narrowed, but operating loss increased as higher impairment charges more than offset lower operating expenses and higher royalty revenue.
- Cash increased by $1.16 million, supported by the equity raise, while operating cash burn remained material.
Outlook, commentary, risks and unusual items
- Liquidity and going concern: Management and the auditor identified substantial doubt about the company’s ability to continue as a going concern, given recurring losses and expected future funding needs. Management believed year-end resources, including $5.43 million net proceeds from the December offering, would fund operations through the first quarter of 2022; additional long-term capital is expected to be needed. The auditor identified the going-concern assessment as a critical audit matter.
- XCART development: A May 2020 Scripps Research agreement provides for up to $3.0 million of research funding over 27 months; $0.9 million had been paid by year-end. A Pharmsynthez work order estimated at $1.8 million covers a Stage 1 research program expected to take about 20 months, with additional milestone payments of up to $1.05 million or, at the company’s discretion, up to 1 million shares.
- Other programs: Pharmsynthez reported positive Epolong trial data and filing a Russian registration dossier in December 2020; subsequent timing and production expectations were partner-reported and not company guidance. Xenetic reported no related revenue in 2020. Takeda royalties were the company’s only reported revenue.
- Financing and dilution: The December registered direct offering sold 2,448,980 shares at $2.45 per share for approximately $6.0 million gross and $5.43 million net. Authorized common shares increased to 50 million. Preferred stock, warrants, options and awards also create potential dilution; preferred stock has liquidation preferences and Series B has anti-dilution provisions.
- Operating and clinical risks: XCART remains preclinical, dependent on external collaborators and future financing, and has no clinical manufacturing arrangement in place. The company has four full-time employees and no in-house manufacturing, sales or marketing capability. Clinical, regulatory, safety, enrollment, intellectual-property and commercialization outcomes are uncertain.
- COVID-19: Management reported no material operational impact during 2020 but said future effects remained uncertain. The filing also discusses market volatility and potential effects on operations and financing.
- Audit and controls: The auditor issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal control, consistent with the company’s filer status.
Important facts for investors to verify
- Whether cash use and XCART spending remain consistent with management’s stated runway through Q1 2022, and when additional financing may be needed.
- Progress, costs, milestones and results under the Scripps and Pharmsynthez XCART agreements, including clinical manufacturing plans and any regulatory discussions or IND timeline.
- Takeda royalty reports and whether Epolong receives Russian authorization, launches, and ultimately generates royalties for Xenetic.
- The assumptions supporting the OncoHist impairment and tax benefit, and whether further asset impairments or tax-asset limitations arise.
- Potential dilution from preferred stock, warrants, equity awards, and any future capital raises; also monitor Nasdaq listing compliance.